Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Buchanan, R. W. Articles by Lehman, A. Search for Related Content PubMed Citation Articles by Buchanan, R. W. Articles by Lehman, A. Schizophrenia Spectrum Disorders Anticonvulsants Antidepressants Anxiolytics Other Somatic Therapy

Relationship of the Use of Adjunctive Pharmacological Agents to Symptoms and Level of Function in Schizophrenia

OBJECTIVE: Adjunctive pharmacological agents are extensively used in the treatment of patients with schizophrenia. This cross-sectional study examined the prevalence of the use of adjunctive agents, the extent to which their use conforms with Schizophrenia Patient Outcomes Research Team (PORT) recommendations for adjunctive pharmacological treatment and the relationship of conformance with treatment recommendations to demographic and clinical variables and to symptoms and level of function. METHOD: Outpatients with schizophrenia (N=344) underwent an extensive interview, and their medical records were reviewed. Data on demographic and clinical characteristics, medications, and role functioning were collected. RESULTS: More than two-thirds of the outpatients received antiparkinsonian agents, and 50% received an adjunctive agent other than an antiparkinsonian agent. Fifty-four (15.7%) outpatients received two or more nonantiparkinsonian adjunctive agents. Rates of conformance with the PORT treatment recommendations for the use of adjunctive agents ranged from 49% to 65%, depending on the type of agent. Ethnicity and diagnosis were the only two patient characteristics that were consistently related to conformance with PORT treatment recommendations. The treatment recommendation for adjunctive mood stabilizers was the only recommendation for which conformance was related to multiple measures of patients’ symptoms and level of function. CONCLUSIONS: Adjunctive agents are widely used in the pharmacological treatment of patients with schizophrenia, but there is a limited relationship between use of these agents in conformance with treatment recommendations and measures of symptoms and level of function. Longitudinal, prospective studies are needed to demonstrate the clinical utility of adjunctive agents.

This article has been cited by other articles:

				M. H. Chakos, I. D. Glick, A. L. Miller, M. B. Hamner, D. D. Miller, J. K. Patel, A. Tapp, R. S. E. Keefe, and R. A. Rosenheck Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial Psychiatr Serv, August 1, 2006; 57(8): 1094 - 1101. [Abstract] [Full Text] [PDF]

				A. M. Mortimer Another triumph of hope over experience?: REVISITING... TREATMENT OF THE PATIENT WITH LONG-TERM SCHIZOPHRENIA Adv. Psychiatr. Treat., July 1, 2005; 11(4): 277 - 285. [Abstract] [Full Text] [PDF]

				R. Rosenheck, D. Perlick, S. Bingham, W. Liu-Mares, J. Collins, S. Warren, D. Leslie, E. Allan, E. C. Campbell, S. Caroff, et al. Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia: A Randomized Controlled Trial JAMA, November 26, 2003; 290(20): 2693 - 2702. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us